Report flags bottlenecks slowing women’s health care and drug development

A new cross-sector report from Women's HealthX says fragmented care, weak foundational research and payer barriers are delaying diagnosis and blocking commercialization of new women’s health therapies. The findings point to problems across the care and development pipeline, from endometriosis diagnosis to reimbursement for sex-specific treatments.

Why it matters: - The report says women's health is facing bottlenecks at both the clinical front door and the drug-development back end. - Those gaps are delaying care for years and slowing the launch of new therapies. - The findings suggest that more investment alone will not fix delivery problems without changes to diagnosis, evidence generation and reimbursement.

What happened: - Women's HealthX released The Women's Health Infrastructure Report 2026 on Sept. 23, 2026. - The report draws on a cross-sector pulse of operational decision-makers across health plans, health systems, biopharma and employers. - The report includes proprietary data and original commentary from clinical, pharmaceutical and enterprise leaders. - Women's HealthX said the report identifies where the women's health system is breaking down.

The details: - The report says systemic knowledge gaps and fragmented care models contribute to years-long diagnostic delays for chronic inflammatory diseases. - The report says frontline diagnostic tools often leave clinicians in an ambiguous gray zone. - That ambiguity can drive unnecessary interventions and delay access to specialist care. - The report says 54% of biopharma and life sciences leaders cite payer reimbursement as their biggest hurdle in launching new sex-specific therapeutics. - That share is higher than regulatory compliance or clinical efficacy, according to the report. - The report says current standard-of-care options for widespread conditions still rely heavily on legacy treatments. - The report argues that women's health needs therapies that target root biological causes, not only symptom management. - Fiona Marshall, president of biomedical research at Novartis, said many women's health indications still lack validated biomarkers, predictive preclinical models and clear regulatory pathways. - Marshall said many conditions that disproportionately affect women remain biologically under-characterized and under-invested. - Dr. Sarah Cigna, director of the Sexual Health and Gender Affirmation Center at George Washington University, said prior authorizations are highly disruptive in daily practice. - Cigna said insurance companies should trust clinicians to decide what is best for individual patients. - Cigna said prior authorizations should be removed because they place insurers between patients and clinicians. - Jacob Marx, CEO of Foravisét and lead research partner for the report, said endometriosis is still too often treated as episodic pain rather than chronic disease. - Marx said the field still depends heavily on hormonal suppression, which may control symptoms but interferes with normal endocrine and reproductive function. - Marx said what is missing is a safe, effective non-hormonal therapy for the disease. - Women's HealthX said barriers to scaling women's health exist at the start of the R&D pipeline and at the final mile of care delivery.

Between the lines: - The report frames women's health as an infrastructure problem, not just a research funding problem. - The biggest friction points appear to be evidence gaps, reimbursement rules and care fragmentation. - The emphasis on payer behavior signals that commercialization risk is now a central issue for developers of sex-specific therapies. - The quotes also point to a broader conflict between clinical autonomy and insurance utilization management.

What's next: - The healthcare ecosystem will gather at Women's HealthX on Dec. 3-4, 2026, at Encore Boston Harbor to address the barriers and advance clinical implementation. - Women's HealthX is offering the full data set and The Women's Health Infrastructure Report 2026 for download. - The company also directs readers to its LinkedIn page for updates: Women's HealthX on LinkedIn.